These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 34587760)

  • 1. Cardiotoxicity of Cancer Treatments: Focus on Anthracycline Cardiomyopathy.
    Nishi M; Wang PY; Hwang PM
    Arterioscler Thromb Vasc Biol; 2021 Nov; 41(11):2648-2660. PubMed ID: 34587760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention.
    Henriksen PA
    Heart; 2018 Jun; 104(12):971-977. PubMed ID: 29217634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection?
    Sawyer DB; Peng X; Chen B; Pentassuglia L; Lim CC
    Prog Cardiovasc Dis; 2010; 53(2):105-13. PubMed ID: 20728697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New signal transduction paradigms in anthracycline-induced cardiotoxicity.
    Ghigo A; Li M; Hirsch E
    Biochim Biophys Acta; 2016 Jul; 1863(7 Pt B):1916-25. PubMed ID: 26828775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anthracycline Chemotherapy and Cardiotoxicity.
    McGowan JV; Chung R; Maulik A; Piotrowska I; Walker JM; Yellon DM
    Cardiovasc Drugs Ther; 2017 Feb; 31(1):63-75. PubMed ID: 28185035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic Changes Associated With Anthracycline-Induced Cardiotoxicity.
    Tantawy M; Pamittan FG; Singh S; Gong Y
    Clin Transl Sci; 2021 Jan; 14(1):36-46. PubMed ID: 32770710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity.
    Chung WB; Youn HJ
    Korean J Intern Med; 2016 Jul; 31(4):625-33. PubMed ID: 27378126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities.
    Vejpongsa P; Yeh ET
    J Am Coll Cardiol; 2014 Sep; 64(9):938-45. PubMed ID: 25169180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anthracycline cardiotoxicity in long-term survivors of childhood cancer.
    Scully RE; Lipshultz SE
    Cardiovasc Toxicol; 2007; 7(2):122-8. PubMed ID: 17652816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The tell-tale heart: molecular and cellular responses to childhood anthracycline exposure.
    Lindsey ML; Lange RA; Parsons H; Andrews T; Aune GJ
    Am J Physiol Heart Circ Physiol; 2014 Nov; 307(10):H1379-89. PubMed ID: 25217655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anthracycline and Peripartum Cardiomyopathies.
    Cowgill JA; Francis SA; Sawyer DB
    Circ Res; 2019 May; 124(11):1633-1646. PubMed ID: 31120822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk.
    Barrett-Lee PJ; Dixon JM; Farrell C; Jones A; Leonard R; Murray N; Palmieri C; Plummer CJ; Stanley A; Verrill MW
    Ann Oncol; 2009 May; 20(5):816-27. PubMed ID: 19153118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management.
    Barry E; Alvarez JA; Scully RE; Miller TL; Lipshultz SE
    Expert Opin Pharmacother; 2007 Jun; 8(8):1039-58. PubMed ID: 17516870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current Views on Anthracycline Cardiotoxicity in Childhood Cancer Survivors.
    Sadurska E
    Pediatr Cardiol; 2015 Aug; 36(6):1112-9. PubMed ID: 25939787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating microRNAs: Potential Markers of Cardiotoxicity in Children and Young Adults Treated With Anthracycline Chemotherapy.
    Leger KJ; Leonard D; Nielson D; de Lemos JA; Mammen PP; Winick NJ
    J Am Heart Assoc; 2017 Apr; 6(4):. PubMed ID: 28377429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of exercise training on cardiotoxicity and cardiac health outcomes in women with breast cancer anthracycline chemotherapy: a study protocol for a randomized controlled trial.
    Antunes P; Esteves D; Nunes C; Sampaio F; Ascensão A; Vilela E; Teixeira M; Amarelo AL; Joaquim A
    Trials; 2019 Jul; 20(1):433. PubMed ID: 31307527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardioprotective Effects and Duration of Beta Blocker Therapy in Anthracycline-Treated Patients: A Systematic Review and Meta-analysis.
    Xu L; Long Y; Tang X; Zhang N
    Cardiovasc Toxicol; 2020 Feb; 20(1):11-19. PubMed ID: 31832905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HFE Gene Variants' Impact on Anthracycline-Based Chemotherapy-Induced Subclinical Cardiotoxicity.
    Vaitiekus D; Muckiene G; Vaitiekiene A; Sereikaite L; Inciuraite R; Insodaite R; Cepuliene D; Kupcinskas J; Ugenskiene R; Jurkevicius R; Juozaityte E
    Cardiovasc Toxicol; 2021 Jan; 21(1):59-66. PubMed ID: 32748118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cardiotoxicity of anthracyclines].
    Costache II; Petriş A
    Rev Med Chir Soc Med Nat Iasi; 2011; 115(4):1200-7. PubMed ID: 22276470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review.
    Bryant J; Picot J; Levitt G; Sullivan I; Baxter L; Clegg A
    Health Technol Assess; 2007 Jul; 11(27):iii, ix-x, 1-84. PubMed ID: 17610809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.